Patrick Ohiani Moru

Patrick Ohiani Moru

Auto-generated profile, based on publicly available information

Patrick Ohiani Moru

Centre of Excellence for Sickle Cell Disease Reasearch & Training(CESRTA), University of Abuja, FCT Abuja, Nigeria

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2023 in Gene Therapy
Verified
Journal Article
Open access
PDF file
NMNchangwi Syntia Munung
Nchangwi Syntia Munung
ONObiageli E. Nnodu
Obiageli E. Nnodu
PMPatrick Ohiani Moru
Patrick Ohiani Moru
AKAkpaka A. Kalu
Akpaka A. Kalu
BIBenido Impouma
Benido Impouma
AWAmbroise Wonkam
Ambroise Wonkam
Somatic gene therapy will be one of the most exciting practices of genetic medicine in Africa and is primed to offer a “new life” for persons living with sickle cell disease (SCD). Recently, successful gene therapy trials for SCD in the USA have sparked a ray of hope within the SCD community in Africa. However, the high cost, estimated to exceed 1.5 million USD, continues to be a major concern for many stakeholders. While affordability is a key global health equity consideration, it is equally important to reflect on other ethical, legal and social issues (ELSIs) that may impact the responsible implementation of gene therapy for SCD in Africa. These include informed consent comprehension, risk of therapeutic misestimation and optimistic bias; priorities for SCD therapy trials; dearth of ethical and regulatory oversight for gene therapy in many African countries; identifying a favourable risk-benefit ratio; criteria for the selection of trial participants; decisional conflict in consent; standards of care; bounded justice; and genetic tourism. Given these ELSIs, we suggest that researchers, pharma, funders, global health agencies, ethics committees, science councils and SCD patient support/advocacy groups should work together to co-develop: (1) patient-centric governance for gene therapy in Africa, (2) public engagement and education materials, and (3) decision making toolkits for trial participants. It is also critical to establish harmonised ethical and regulatory frameworks for gene therapy in Africa, and for global health agencies to accelerate access to basic care for SCD in Africa, while simultaneously strengthening capacity for gene therapy.

4 March 2026 in Hemoglobin
Verified
Journal Article
Open access
ONObiageli Eunice Nnodu
Obiageli Eunice Nnodu
WMWilson Mupfururirwa
Wilson Mupfururirwa
SKSarah Kiguli
Sarah Kiguli
LCLulu Chirande
Lulu Chirande
BTBoubacar Ali Toure
Boubacar Ali Toure
AWAmbroise Wonkam
Ambroise Wonkam
Sickle cell disease (SCD) is caused by an inherited single-nucleotide substitution in both copies of the β-globin gene [HBB(Glu7Val)]. The sickle-cell mutation results in the production of an abnor...

10 September 2026 in BMC Medical Ethics
Verified
Journal Article
Open access
PDF file
PMPatrick Ohiani Moru
Patrick Ohiani Moru
ONObiageli Eunice Nnodu
Obiageli Eunice Nnodu
VNVictoria Nembaware
Victoria Nembaware
RCReuben Ikechukwu Chianumba
Reuben Ikechukwu Chianumba
AOAnthonia Chinenye Okoro
Anthonia Chinenye Okoro
AWAmbroise Wonkam
Ambroise Wonkam
Somatic gene editing targets non-reproductive cells to treat genetic diseases like sickle cell disease (SCD) without affecting future generations. However, there are challenges in obtaining informed consent in sub-Saharan Africa (sSA) due to language barriers, cultural differences, and low health literacy. While promising, somatic gene editing carries risks such as off-target effects, unintended gene transfer, and potential activation of oncogenes. The aims of the review are to conduct an in-depth literature review of the current approaches to informed consent for somatic gene editing and gene therapy and identify potential areas for improvement, specifically in relation to SCD in sSA. Arksey and O’Malley five steps approach was adopted for this scoping review. A combined search via PubMed and EBSCOhost retrieved a total of 57 articles, Screening was conducted and a total of 23 articles were included in this review. Of the 23 articles 5 were original cross-sectional studies, 4 were reports, 10 were literature reviews, and 4 were opinion pieces, most of the articles were conducted in the USA (56.5%) and the least from Africa (4.3%). Themes included Patient Education, Risk Assessment, Paediatric Consideration, Ethical & Legal Consideration, Decision Making/Support, Privacy & Indemnification, Consenting process & Culture. In SSA, the consent process should use simple, clear language and visual aids for complex ideas, respect local customs and cultural norms and involve parents in decisions for children when appropriate. Privacy is a key concern, particularly due to stigmatization of genetic conditions like SCD. Informed consent is essential for gene therapy research in SCD in sSA. It is crucial to conduct a study to assess the level of gene therapy literacy among various stakeholders.